gdc
Kidney Cancer

Drugs for Kidney (Renal-Cell) Cancer

Here are the financial support services available to patients receiving treatment for Kidney (Renal) Cancer.

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-pay Card

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance for Afinitor. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Afinitor for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Afinitor for free for 1 year, or until a prescription drug coverage becomes available to them.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with interferon-alfa, for the treatment of patients with metastatic renal-cell carcinoma.

Genentech offers 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Card

For privately insured patients, the program ensures a copay of $25 for Avastin, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Avastin free of charge to uninsured and underinsured patients whose household income is less than $100,000. Avastin is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of the income (regardless of insurance).

Cabometyx (cabozantinib)

Drug company: Exelixis
844-900-3273

Cabometyx is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Exelixis Access Services offers 4 financial assistance programs for patients using Cabometyx:

EASE Co-pay Assistance Program

Patients with private insurance who are eligibile for this program will pay no more than $10 monthly for out-of-pocket prescription costs for Cabometyx.

EASE Quick Start Program

Eligible patients who experience a delay of more than 5 days in the processing or approval of their prescription can receive a 15-day supply of Cabometyx with refills as needed (up to 60 days).

EASE Patient Assistance Program

This program provides Cabometyx free of charge to qualifying patients who are uninsured or underinsured.

Dose Exchange Program

Patients who require a dose reduction to their therapy with Cabometyx can receive a free, 1-time supply of Cabometyx tablets in the new dose strength.

Inlyta (axitinib)

Drug company: Pfizer
877-744-5675

Inlyta is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Inlyta:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Inlyta is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Inlyta for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Inlyta for free.

Lenvima (lenvatinib)

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used, in combination with everolimus, for the treatment of patients with advanced renal-cell carcinoma.

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.

Eisai Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Nexavar (sorafenib) Tablets

Drug company: Bayer
866-639-2827

Nexavar is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Bayer offers 2 financial assistance programs for patients using Nexavar:

Nexavar $0 Co-Pay Program

With this program, patients with private insurance pay $0 copay for Nexavar, and the program pays up to $25,000 annually, with no monthly maximum.

REACH Patient Assistance Program

Uninsured or underinsured patients can contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Bristol-Myers Squibb (BMS) Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Opdivo, may be eligible for help paying for their prescription if they are being treated as an outpatient and have an annual income of less than 300% of the federal poverty level.

Sutent (sunitinib malate) Capsules

Drug company: Pfizer
877-744-5675

Sutent is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Sutent:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Sutent is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Sutent for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Sutent for free.

Torisel (temsirolimus)

Drug company: Pfizer
877-744-5675

Torisel is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Pfizer Oncology Together offers 1 financial assistance program for patients using Torisel:

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Torisel for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Torisel for free.

Votrient (pazopanib)

Drug company: Novartis
800-245-5356

Votrient is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Votrient:

Novartis Oncology Universal Co-Pay Card

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance for Votrient. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Votrient for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Votrient for free for 1 year, or until a prescription drug coverage becomes available to them.

Table. Drugs Prescribed for Kidney (Renal-Cell) Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services








    Drug name (generic name)
  • Torisel (temsirolimus)
  • Drug company
  • Pfizer
  • Indication
  • Advanced renal-cell carcinoma
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675


Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country